Eight weeks. That's how long my wife and I have been in Houston, where I entered a Phase 1 drug trial for ABT-199, a new experimental drug that may provide at least a long-term solution, if not a cure, for my chronic lymphocytic leukemia (CLL).

We came not knowing what would happen or what to expect. We were amateurs, neophytes, newbies, 76-year-old children going to the doctor for the first time, figuratively speaking.
<...